ERBB2 and breast cancer: The introduction of targeted anti-HER2 therapies has improved outcomes in a significant fraction of BC patients with HER2-positive disease; however, 15% of patients will still develop distant metastasis/recurrence despite having undergone current consensus state-of-the-art local and systemic treatment protocols [45].